Get the Stockscreener App
0.9494
4.09%
0.0373
NanoViricides Inc stock is traded at $0.9494, with a volume of 44,401.
It is up +4.09% in the last 24 hours and down -9.58% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$0.9121
Open:
$0.95
24h Volume:
44,401
Relative Volume:
0.17
Market Cap:
$20.50M
Revenue:
-
Net Income/Loss:
$-8.32M
P/E Ratio:
-1.9713
EPS:
-0.4816
Net Cash Flow:
$-7.43M
1W Performance:
+0.26%
1M Performance:
-9.58%
6M Performance:
-34.07%
1Y Performance:
-18.16%
1-Day Range:
$0.92
$0.9634
1-Week Range:
$0.87
$0.9825
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
0.9494 | 19.70M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
451.70 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.89 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.41 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.07 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
165.09 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NanoViricides to begin Phase II trial of MPox treatment in Congo - Proactive financial news
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides - ACCESS Newswire
Monkeypox drug trial cleared in Congo as NanoViricides readies dosing - Stock Titan
Tangible book value per share of NanoViricides, Inc. – MUN:NV3P - TradingView
Forecast Cut: Is NanoViricides Inc subject to activist investor interest2026 Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Reviewing NanoViricides (NYSE:NNVC) & Spruce Biosciences (NASDAQ:SPRB) - Defense World
Growth Recap: Should I hold or sell NanoViricides Inc nowTrade Ideas & Risk Controlled Daily Plans - baoquankhu1.vn
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - chartmill.com
Aug Retail: Can NanoViricides Inc generate free cash flowEarnings Beat & Real-Time Volume Analysis - baoquankhu1.vn
NanoViricides (NYSE:NNVC) Stock Price Down 4.8% – What’s Next? - Defense World
If You Invested $1,000 in Nanoviricides (NNVC) - Stock Titan
EBITDA per share of NanoViricides, Inc. – FWB:NV3P - TradingView
Volume Recap: Can NanoViricides Inc grow without external funding2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Beaver County Times
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - The Register-Guard
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Asheville Citizen Times
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - ACCESS Newswire
NanoViricides Completes Manufacturing of NV-387 Oral Gummies, Prepares for Phase II Monkeypox Trial - citybuzz -
Aug Setups: Can NanoViricides Inc continue delivering strong returns2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
Small cap wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium… - Proactive Investors
NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial - Yahoo! Finance Canada
Antiviral NV-387 heads to Phase II mpox trial with new gummy form - Stock Titan
Jobs Data: Can NanoViricides Inc continue delivering strong returnsMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
Sell Signal: Is NanoViricides Inc subject to activist investor interest2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
NNVC Earnings History & Surprises | EPS & Revenue Results | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Asheville Citizen Times
getLinesFromResByArray error: size == 0 What is NanoViricides Inc.’s TAM (Total Addressable Market)Portfolio Gains Report & Growth Focused Entry Reports - mfd.ru
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - The Clarion-Ledger
US Stocks Recap: Is NanoViricides Inc forming a breakout patternJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Aug Fed Impact: Can NanoViricides Inc continue delivering strong returnsQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387ICYMI - Proactive financial news
Growth Value: Will NanoViricides Inc benefit from rate cutsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Small cap wrap: Aftermath Silver, M2i Global, NanoViricides, AtaiBeckley… - Proactive financial news
NanoViricides advances toward fully funded Phase II MPox trial in DRC - Proactive financial news
NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Yahoo Finance
NanoViricides: Fiscal Q2 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Second Quarter Earnings Overview - Bitget
Moving Averages: Is NanoViricides Inc exposed to political riskJuly 2025 Movers & Growth Focused Stock Reports - baoquankhu1.vn
Can NanoViricides Inc grow without external fundingJuly 2025 Review & Growth Focused Stock Reports - baoquankhu1.vn
Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news
NanoViricides seeks FDA orphan status for MPox drug - Yahoo Finance
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget
New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):